[HTML][HTML] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases

K Dong, W Liang, S Zhao, M Guo, Q He… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell …

ZY He, MF Li, JH Lin, D Lin, RJ Lin - Cancer management and …, 2019 - Taylor & Francis
Background Non-small-cell lung cancer (NSCLC) is a global public health problem, and
brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy …

[HTML][HTML] First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review …

Y Song, S Lin, J Chen, J Dang - BMC cancer, 2023 - Springer
Background It remains uncertain whether first-line treatment with upfront brain radiotherapy
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …

[HTML][HTML] Efficacy and safety of radiotherapy plus EGFR-TKIs in NSCLC patients with brain metastases: a meta-analysis of published data

X Wang, Y Xu, W Tang, L Liu - Translational oncology, 2018 - Elsevier
Background: The role of radiotherapy (RT) combined with epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with …

[PDF][PDF] Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis

W Wang, Z Song, Y Zhang - Archives of Medical Science, 2018 - termedia.pl
Results In 49 symptomatic BM patients, the median OS of the stereotactic radiosurgery
(SRS)-treated group was longer than in the whole brain radiotherapy (WBRT) group (37.7 …

[HTML][HTML] EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases

T Jiang, C Su, X Li, C Zhao, F Zhou, S Ren… - Journal of Thoracic …, 2016 - Elsevier
Introduction Whether EGFR tyrosine kinase inhibitors (TKIs) plus whole brain radiation
therapy (WBRT) provide a better survival benefit than EGFR TKIs alone remains …

[HTML][HTML] Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: a single institution retrospective …

H Chen, A Wu, H Tao, D Yang, Y Luo, S Li, Z Yang… - Medicine, 2018 - journals.lww.com
Concurrent versus sequential whole brain radiotherapy and TK... : Medicine Concurrent versus
sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain …

[HTML][HTML] Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant …

Q Zhu, Y Sun, Y Cui, K Ye, C Yang, D Yang, J Ma… - Oncotarget, 2017 - ncbi.nlm.nih.gov
This study compared treatment outcomes between TKI monotherapy and TKI administration
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR …

Y Chen, J Yang, X Li, D Hao, X Wu, Y Yang… - Cancer …, 2016 - Wiley Online Library
We proposed to compare the outcomes of first‐line epidermal growth factor receptor–
tyrosine kinase inhibitor (EGFR‐TKI) alone with EGFR‐TKI plus whole‐brain radiotherapy …

EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data

Y Fan, X Xu, C Xie - OncoTargets and therapy, 2014 - Taylor & Francis
Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …